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AbstrAct
Objective The myosin- binding protein C (MYBPC3) 
c.927- 2A>G founder mutation accounts for >90% 
of sarcomeric hypertrophic cardiomyopathy (HCM) 
in Iceland. This cross- sectional observational study 
explored the penetrance and phenotypic burden among 
carriers of this single, prevalent founder mutation.
Methods We studied 60 probands with HCM caused 
by MYBPC3 c.927- 2A>G and 225 first- degree relatives. 
All participants underwent comprehensive clinical 
evaluation and relatives were genotyped.
Results Genetic and clinical evaluation of relatives 
identified 49 genotype- positive (G+) relatives with left 
ventricular hypertrophy (G+/LVH+), 59 G+without LVH 
(G+/LVH−) and 117 genotype- negative relatives 
(unaffected). Compared with HCM probands, G+/
LVH+ relatives were older at HCM diagnosis, had 
less LVH, a less prevalent diastolic dysfunction, 
fewer ECG abnormalities, lower serum N- terminal 
pro- B- type natriuretic peptide (NT- proBNP) and 
high- sensitivity cardiac troponin I levels, and fewer 
symptoms. The penetrance of HCM was influenced 
by age and sex; specifically, LVH was present in 39% 
of G+males but only 9% of G+females under age 40 
years (p=0.015), versus 86% and 83%, respectively, 
after age 60 (p=0.89). G+/LVH− subjects had normal 
wall thicknesses, diastolic function and NT- proBNP 
levels, but subtle changes in LV geometry and more ECG 
abnormalities than their unaffected relatives.
Conclusions Phenotypic expression of the Icelandic 
MYBPC3 founder mutation varies by age, sex and 
proband status. Men are more likely to have LVH at a 
younger age, and disease manifestations were more 
prominent in probands than in relatives identified via 
family screening. G+/LVH− individuals had subtle 
clinical differences from unaffected relatives well into 
adulthood, indicating subclinical phenotypic expression 
of the pathogenic mutation.
IntROduCtIOn
Hypertrophic cardiomyopathy (HCM) 
is a genetically heterogeneous disorder 
with highly variable clinical expression. 
Although most HCM mutations occur in 
two cardiac sarcomere protein genes, MHY7 
(encoding β-myosin heavy chain) and 
MYBPC3 (encoding myosin- binding protein 
C), specific pathogenic variants are usually 
unique to one or a few families. The small 
numbers of individuals with identical HCM 
mutations, the great diversity in background 
genotypes and the substantial phenotypic 
heterogeneity has limited the ability to deter-
mine the impact of genotype on phenotype 
and clinical outcomes. Studying populations 
Key questions
What is already known about this subject?
 ► Hypertrophic cardiomyopathy (HCM) is the most 
common monogenic heart disease, with diverse ge-
netic and phenotypic expression. More than 2000 
causative mutations in at least eight genes have 
been described in association with HCM. Although 
mutations in myosin- binding protein C (MYBPC3) 
represent 30%–40% of all HCM mutations, most of 
the causal mutations are usually unique to one or 
few families.
What does this study add?
 ► A prevalent MYBPC3 founder mutation is respon-
sible for >90% of sarcomere HCM in Iceland, pro-
viding valuable opportunity to explore associations 
between genotype and clinical phenotype. To our 
knowledge, this is the largest and most compre-
hensive genotype–phenotype study that exists on a 
single HCM mutation. Phenotypic manifestations of 
the Icelandic MYBPC3 founder mutation varied by 
age, sex and proband status, and were remarkably 
similar to other distinct founder populations with 
truncating MYBPC3 variants, suggesting a common 
effect in the context of haploinsufficiency in the 
myosin- binding protein.
How might this impact on clinical practice?
 ► Our findings underscore the need for lifelong sur-
veillance of male and female MYBPC3 mutation 
carriers, and identifying factors that modify disease 
expression and drive phenotypic progression.
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with founder mutations helps address some of these chal-
lenges, but to date, only a few analyses have systematically 
described HCM phenotypes caused by founder mutations 
in at- risk relatives.1 2
We previously reported an Icelandic MYBPC3 founder 
mutation, c.927- 2A>G, that was introduced ~500 years 
ago and has an estimated population prevalence of 
0.36%. This single mutation is responsible for >90% of 
sarcomeric HCM in Iceland,3 a geographically isolated 
country with a relatively homogeneous population. Here, 
we explored the inheritance and clinical consequences 
of the Icelandic MYBPC3 founder mutation in 60 HCM 
probands and 225 first- degree relatives. Because the prev-
alence of the Icelandic variant is higher than that seen in 
other single founder variants,1 4–7 it provides a valuable 
opportunity to explore associations between genotype 
and clinical phenotype at a larger scale.
MetHOds
study design and population
This study used a cross- sectional observational cohort 
design. HCM probands had a previously established HCM 
diagnosis and were found to carry the MYBPC3 c.927- 
2A>G founder mutation through a nationwide genetic 
study of HCM in Iceland.3 deCODE Genetics genealog-
ical database was used to identify all first- degree relatives. 
None of the relatives were previously diagnosed with 
HCM. Relatives were grouped according to genotype and 
the presence or absence of left ventricular hypertrophy 
(LVH; defined as a LV wall thickness (LVWT) ≥12 mm in 
adults or a z- score of ≥2 in children) as follows: mutation 
carrier with LVH (G+/LVH+), mutation carrier without 
LVH (G+/LVH−) and healthy mutation- negative (unaf-
fected).
Participants underwent study visit between November 
2012 and June 2014, including assessment of medical 
history and heart failure symptoms (New York Heart Asso-
ciation functional class), blood pressure, ECG and stan-
dardised echocardiography. Blood was drawn for genetic 
analysis and serum biomarker analysis. Subjects with 
known hypertension, cardiovascular disease other than 
HCM or medical conditions associated with increased 
collagen turnover were excluded. All investigators were 
blinded to the subjects’ clinical and genetic status. This 
study complied with the Declaration of Helsinki and was 
approved by the National Bioethics Committee of Iceland 
and the Icelandic Data Protection Authority. Informed 
consent was obtained from all participants, and parental 
consent was obtained for participants under 18 years of 
age.
Genetic analysis
Genomic DNA, extracted from whole- blood samples, was 
obtained from all relatives and genotyped to determine 
the presence or absence of the MYBPC3 c.927- 2A>G 
mutation, as previously described.3
echocardiography
Transthoracic echocardiograms were obtained using 
Vivid E9 ultrasound systems (GE Healthcare, Horten, 
Norway), including two- dimensional images, spectral, 
colour and tissue Doppler interrogation following a 
standardised protocol. The average of three cardiac 
cycles was used for measurements of cardiac dimen-
sions, mitral inflow patterns and myocardial velocities 
according to published guidelines.8 9 Maximal LVWT was 
defined by the maximal LVWT in any of the LV segments 
measured in the long- axis or short- axis parasternal view. 
Relative wall thickness was defined as two times the 
posterior wall thickness divided by the LV end- diastolic 
diameter (LVEDD). Left atrial (LA) volumes were meas-
ured using the biplane disk summation at end- systole. To 
allow comparisons between subjects with different body 
sizes, chamber measurements were reported as indexed 
to body surface area (BSA). The peak instantaneous LV 
outflow tract gradient was measured at rest and during 
the Valsalva manoeuvre with continuous- wave Doppler. 
The pattern of LV septal hypertrophy was divided into 
the following morphological subtypes: reverse curvature, 
sigmoid, neutral and apical.10 Diastolic function was 
assessed and graded as normal or diastolic dysfunction 
grades 1–3 based on expert consensus recommenda-
tions.9 Images were analysed offline using Echopac BT 
112 software (GE Healthcare, Horten, Norway). Echo-
cardiograms were analysed by two observers with exper-
tise in cardiac imaging (BA, GTG) without knowledge of 
genotypes.
eCG
Standard 12- lead ECGs were obtained at rest in the supine 
position. All ECGs were analysed by a single investigator 
(BA) according to standard criteria as described else-
where.11 The Sokolow–Lyon LVH voltage criteria were 
defined as SV1 + RV5 or RV6 ≥35 mm. The Cornell LVH 
voltage criteria were defined as a RaVL+ SV3>28 mm for 
men and >20 mm for women. Conduction disturbance 
included interventricular conduction delay (QRS dura-
tion ≥110 ms), left bundle branch block or right bundle 
branch block. QST was defined as the presence of patho-
logical Q waves, T wave inversion or ST- segment depres-
sion.11
serum biomarkers
Plasma concentrations of N- terminal B- type natriu-
retic peptide (NT- proBNP), high- sensitivity troponin I 
(hsTnI) and carboxy- terminal propeptide of procollagen 
type I (PICP) were measured. Plasma concentrations of 
NT- proBNP and hsTnI were measured in the Biomarker 
Research and Clinical Trials Laboratory at Brigham and 
Women’s Hospital, Boston, MA. NT- proBNP was meas-
ured using the proBNPII immunoassay (Roche, Indian-
apolis, IN, USA) with a coefficient of variation (CV) of 
3.8% at 127 pg/mL and 2.4% at 4180 pg/mL. hsTnI was 
measured using an ultrasensitive immunoassay utilising 
a single- molecule counting technology (Erenna hsTnI, 
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Figure 1 A flow diagram demonstrating the study cohort. 
*27 individuals were excluded due to hypertension and/or 
coronary artery disease, and 2 because of metastatic cancer.
Singulex, Palo Alto, CA, USA) with a CV of 12.5% at 
6.8 ng/L and 13.7% at 39.2 ng/L. PICP was measured 
at the CIMA of University of Navarra, Pamplona, Spain, 
using the METRA Enzyme Immunoassay (Quidel Corpo-
ration) with an inter and intra- assay CV of 6.3% and 6.4%, 
respectively, and a lower limit of detection of 0.2 ug/L. 
All assays were performed using commercially available 
reagents by technicians blinded to clinical and genetic 
statuses of the subjects. Details have been described previ-
ously.12 13
statistical analysis
Descriptive data are presented as the means±SD or counts 
and proportions. Baseline characteristics were compared 
with Student’s t test for continuous variables, and the 
χ2 test or Fisher’s exact test for categorical variables, as 
appropriate. Generalised linear models were used to 
examine differences in echocardiographic measures, 
ECGs and biomarkers, adjusting for age, sex and within- 
family correlation, where correlation between relatives 
was assumed to be proportional to their kinship. Values 
are expressed as the adjusted means (SE). Biomarkers 
were log- transformed due to skewed distributions, 
and values below the detectable threshold were set to 
the lower detection limit (0.1 pg/mL; n=9 for hsTnI). 
Pearson correlation coefficients were calculated to assess 
correlations between continuous variables. P values of 
<0.05 were considered statistically significant.
Results
study population
We studied 285 individuals, including 60 HCM probands 
(mean age, 53±17 years) described previously3 and 225 
first- degree relatives (figure 1). Of the relatives, 108 
(48%) were founder mutation carriers (G+; mean age 
41±20 years) and 117 (52%) were healthy mutation- 
negative individuals (unaffected; mean age, 40±18 years). 
Among the G+ relatives, 49 (45%) were G+/LVH+ (mean 
age, 50±19 years) and 59 were G+/LVH− (mean age, 
34±17 years).
Baseline clinical characteristics
Baseline demographics are summarised in table 1. HCM 
probands and G+/LVH+ relatives were predominantly 
men (67% and 55%, respectively). The probands were 
diagnosed with HCM at younger ages (41±14 years) than 
G+/LVH+ relatives (50±19 years; p value=0.004) and had 
more symptoms (48% HCM probands vs 4% G+/LVH+ 
relatives were New York Heart Association (NYHA) func-
tional class ≥II; p<0.0001). Although the majority (96%) 
of G+/LVH+ relatives were asymptomatic, one (8.2%) 
had a history of atrial fibrillation, four (8.2%) had expe-
rienced unexplained syncope and one (2%) had been 
hospitalised for symptomatic heart failure.
G+/LVH− relatives were predominantly women (68%); 
98% had no symptoms (NYHA class I) and none had a 
history of atrial fibrillation.
echocardiographic findings
Echocardiographic findings are summarised in table 2. 
There was considerable variation in LVWT (figure 2A) 
among HCM probands and G+/LVH+ relatives across all 
ages, but the HCM probands had ~40% greater maximal 
LVWT overall. HCM probands also exhibited greater 
variation in LA size and larger mean LA volumes than 
their G+/LVH+ relatives (figure 2B). Furthermore, HCM 
probands had higher LV outflow tract gradients, LVWT 
to LVEDD ratios and more prominent diastolic abnor-
malities (figure 3) than G+/LVH+ relatives. Cardiac 
morphology showed a reverse curvature septum in 90% 
of the HCM probands, compared with 69% of the G+/
LVH+ relatives (p=0.019), while 7% of the probands 
and 22% of the G+/LVH+ relatives had neutral septum 
morphology (p=0.040). Sigmoid septum morphology or 
apical hypertrophy was rare in both groups.
The mean LVWT was slightly higher in G+/LVH− 
compared with unaffected relatives (9.9±0.2 vs 9.5±0.1, 
p=0.032), as was the relative wall thickness and ratio of 
LVWT to LVEDD (table 2). However, when compared 
across the age span of all study participants, neither LVWT 
nor LA volumes were substantially different between G+/
LVH− and unaffected relatives (figure 1A and B). Simi-
larly, diastolic function (figure 2) did not distinguish G+/
LVH− relatives from unaffected relatives.
serum biomarkers
NT- proBNP (reflecting haemodynamic stress) and hsTnI 
(reflecting myocardial injury) levels were significantly 
higher in HCM probands than in G+/LVH+ relatives 
(table 2). NT- proBNP levels were higher in G+/LVH− 
relatives than in unaffected relatives, but hsTnI and PICP 
(reflecting collagen synthesis) levels were comparable.
eCG
ECGs were abnormal in 87% of the HCM probands and 
57% of the G+/LVH+ relatives (p=0.0002; figure 4). In 
contrast, 27% of the G+/LVH− relatives and 15% of the 
unaffected relatives had abnormal ECGs (p=0.028). Repo-
larisation abnormalities and/or Q waves (QST) were 
the most frequently observed abnormalities and were 
present in 77% of G+/LVH+ probands and 49% of G+/
LVH+ relatives (p=0.003). QST was present in 20% of G+/
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(n=60) (n=49) (n=59) (n=117)
Age at enrolment, years 53±17 50±19 34±17 40±18 0.379 0.100
Age at HCM diagnosis, years 41±14 50±19 0.004
Male 40 (67%) 27 (55%) 19 (32%) 55 (47%) 0.217 0.060
Reason for diagnosis
  Symptoms 24 (40%)
  Incidental finding* 22 (37%)
  Prior screening† 14 (23%)
  Body surface area (kg/m2) 2.01±0.22 1.99±0.23 1.76±0.30 1.92±0.36 0.982 0.169
Blood pressure, mm Hg
  Systolic 120±13 125±12 117±13 122±14 0.037 0.360
  Diastolic 73±9 75±10 70±9 74±10 0.075 0.605
NYHA class <0.0001 0.994
  I 31 (52%) 47 (96%) 58 (98%) 115 (98%)
  II 26 (43%) 2 (4%) 1 (2%) 2 (2%)
  III 3 (5%) 0 0 0
  IV 0 0 0 0
Medication use
  Amiodarone 5 (8%) 1 (2%) 0 0 0.152
  Anticoagulation 4 (7%) 1 (2%) 0 0 0.251
  ACE inhibitor/ARB 10 (17%) 0 0 0 0.021
  β-blocker 36 (60%) 11 (22%) 3 (5%) 0 <0.0001 0.036
  Calcium channel blocker 6 (10%) 3 (6%) 0 0 0.464
  No cardiovascular medications 17 (28%) 37 (76%) 56 (95%) 117 (100%) <0.0001 0.036
History of atrial fibrillation 11 (18%) 4 (8%) 0 0 0.126
Heart failure hospitalisation 6 (10%) 1 (2%) 0 0 0.129
History of stroke/TIA 0 0 0 1 (0.9%) 1.00
Unexplained syncope 11 (18%) 4 (8%) 0 0 0.135
Implantable cardioverter defibrillator 11 (18%) 0 0 0 <0.0001
Values are means±SD or numbers and proportions (%). P values for body surface area and blood pressure were adjusted for age and 
sex.
*12 had abnormal ECGs, 3 were examined because of heart murmurs and five underwent echocardiography due to other reasons.
†14 individuals were diagnosed through prior screening 14±9 years ago.
ACE, angiotensin- converting enzyme; ARB, angiotensin receptor blocker; G+, genotype positive; HCM, hypertrophic cardiomyopathy; 
LVH, left ventricular hypertrophy; NYHA, New York Heart Association; TIA, transient ischaemic attack.
LVH− relatives and 15% of unaffected relatives (p=0.07). 
The Sokolow–Lyon and Cornell voltage criteria had poor 
sensitivity for identifying LVH in HCM probands (15% and 
27%, respectively) and G+/LVH+ relatives (8.2% and 12%, 
respectively).
Penetrance
The penetrance of LVH in G+family members (n=108) was 
age- and sex- dependent (figure 5). LVH was identified in 
G+/LVH+ relatives at ages spanning from 11 to 88 years, 
with a maximal LVWT ranging from 11 to 29 mm. Among 
G+ relatives aged under 40 years, 39% of men but only 9% 
of women had LVH (p=0.015). In contrast, after 60 years of 
age, the prevalence of LVH was high (83%–86%) in both 
sexes, but not complete. The oldest G+/LVH− male was 70 
years old, and the oldest G+/LVH− female was 81 years old.
dIsCussIOn
Analyses of cardiac imaging, ECG and serum biomarker 
studies in a nationwide cohort provided insights into 
the clinical expression and penetrance of a highly prev-
alent Icelandic HCM founder mutation, MYBPC3 c.927- 
2A>G. Among the G+ relatives, 45% had LVH at the time 
of the study. Female mutation carriers developed LVH 
later in life than males. Before the age of 40 years, the 
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(n=60) (n=49) (n=59) (n=117)
Maximal LVWT, mm 24.9 (0.7) 18.2 (0.8) 9.9 (0.2) 9.5 (0.1) <0.0001 0.032
LVEDD, mm 42.8 (1.0) 44.0 (1.0) 45.1 (0.7) 46.4 (0.5) 0.409 0.116
LVEDD indexed to BSA, mm/m2 21.7 (0.5) 22.4 (0.5) 25.0 (0.6) 25.4 (0.4) 0.249 0.695
LVESD, mm 27.1 (0.8) 27.6 (0.9) 29.0 (0.6) 30.2 (0.4) 0.717 0.059
LVESD indexed to BSA, mm/m2 13.7 (0.4) 14.0 (0.4) 16.1 (0.4) 16.42 (0.3) 0.619 0.331
Left atrial diameter, mm 42 (0.9) 40.0 (1.0) 33.6 (0.6) 34.2 (0.4) 0.109 0.406
Left atrial volume indexed to BSA, mm/m2 46.0 (2.3) 37.3 (2.4) 24.6 (0.9) 25.2 (0.6) 0.008 0.596
Ratio of LVWT to LVEDD 0.61 (0.02) 0.42 (0.02) 0.23 (0.005) 0.20 (0.004) <0.0001 0.008
Relative wall thickness 0.51 (0.02) 0.42 (0.02) 0.37 (0.01) 0.34 (0.007) 0.001 0.025
LVEF, % 64.0 (1.5) 66.4 (1.5) 64.9 (1.0) 63.9 (0.7) 0.267 0.350
Peak LV outflow tract gradient, mm Hg 18.3 (3.0) 8.0 (3.1) 7.1 (0.3) 6.7 (0.2) 0.011 0.255
Peak LV outflow tract gradient>30 mm Hg 9 (15%) 0 0 0 0.003
Tissue Doppler velocities:
  Septal E', cm/s 5.7 (0.3) 8.1 (0.3) 10.1 (0.3) 9.8 (0.2) <0.0001 0.384
  Lateral E', cm/s 8.2 (0.4) 10.7 (0.4) 13.6 (0.4) 13.2 (0.3) <0.0001 0.395
  Septal S', cm/s 7.0 (0.2) 7.7 (0.23) 8.3 (0.20) 8.2 (0.1) 0.025 0.956
  Lateral S', cm/s 7.4 (0.3) 9.0 (0.30) 10.2 (0.3) 9.7 (0.2) 0.0001 0.278
  Septal E/E' ratio, cm/s 15.6 (0.8) 10.7 (0.86) 8.5 (0.3) 8.7 (0.2) <0.0001 0.549
  Lateral E/E' ratio, cm/s 11.4 (0.7) 8.3 (0.8) 6.4 (0.3) 6.6 (0.2) 0.003 0.761
Septal morphology:
  Reverse curvature septum 54 (90%) 34 (69%) 0.019
  Sigmoid septum 2 (3.3%) 1 (2.0%) 0.488
  Apical hypertrophy 0 3 (6.1%) 0.052
  Neutral septum 4 (6.7%) 11 (22%) 0.040
Biomarkers
  NT- proBNP, pg/ml 349 (1.2) 116 (1.2) 50.8 (1.1) 34.6 (1.1) <0.0001 <0.0001
  High- sensitivity troponin I, ng/mL 12.3 (1.2) 3.9 (1.2) 1.4 (1.1) 1.1 (1.1) <0.0001 0.332
  PICP, µg/L 103 (4.7) 100 (5.0) 122 (5.5) 118 (3.8) 0.749 0.329
Values are adjusted means (SE) or numbers and proportions (%). P values were adjusted for age, sex and within- family correlation.
BSA, body surface area; LV, left ventricular; LVEDD, left ventricular end- diastolic dimension; LVEF, left ventricular ejection fraction; 
LVESD, left ventricular end- systolic dimension; LVWT, left ventricular wall thickness; NT- proBNP, N- terminal pro- B natriuretic peptide; 
PICP, carboxy- terminal propeptide of procollagen type I.
penetrance of LVH was 9% in G+ females in contrast to 
39% in G+ males. However, LVH was present in >80% 
in both sexes after the age of 60 years, indicating a high 
lifetime penetrance of HCM. Although HCM probands 
and G+/LVH+ relatives were of comparable ages at the 
time of the study, HCM probands had a greater burden 
of disease, including more severe hypertrophy and dias-
tolic dysfunction, more arrhythmias and clinical symp-
toms, and higher serum troponin and natriuretic peptide 
levels. G+/LVH− individuals had subtle differences in 
LV geometry compared with their unaffected relatives, a 
higher prevalence of ECG abnormalities and a modest, 
intra- normal elevation of NT- proBNP levels. Collectively, 
these findings provide evidence for early LV remodelling 
and haemodynamic stress prior to the development of 
LVH.
Age- and sex-related penetrance
There was substantial variation in age of diagnosis and 
the degree of LVH among the G+ relatives identified 
through family screening that appears to be associated 
with both age and sex. LVH was rarely seen in children 
or adolescents carrying this MYBPC3 founder mutation. 
Our results confirm the male predominance and earlier 
onset of clinical disease previously described in HCM.14–16 
However, we make a novel observation that this imbalance 
attenuates with advancing age. Notably, the prevalence of 
LVH in female mutation carriers increased considerably 
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Figure 2 Scatter plots stratified by genotype–phenotype showing the relationship between (a) age and LVWT. There was 
no correlation between age and LVWT in HCM probands (red line, r=−0.11, p=0.42) and G+/LVH+ relatives (blue line, r=0.14, 
p=0.32). A modest linear increase in LVWT by age was noted in G+/LVH− relatives (green line, r=0.32, p=0.015) and unaffected 
relatives (black line, r=0.38, p<0.0001). (b) Age and LA volume indexed to BSA. There was a significant relationship between 
LA volume and age in G+/LVH+ relatives (blue line, r=0.49, p=0.0003), while there was no significant correlation among HCM 
probands (red line, r=0.17, p=0.19), G+/LVH- relatives (green line, r=−0.07, p=0.61) and unaffected relatives (black line, r=−0.02, 
p=0.81).
Figure 3 Stacked column bars demonstrating LV diastolic 
function for each group. HCM probands had significantly 
worse diastolic function than their G+/LVH+ relatives. 
Diastolic function was normal in 38% of HCM probands, 
71% of G+/LVH+ relatives, 97% of G+/LVH− relatives and 
95% of unaffected relatives. P values were adjusted for age, 
sex and within- family correlation.
Figure 4 Frequency of ECG abnormalities among each 
group. ECG abnormalities, including Cornell voltage criteria, 
Q waves and/or repolarisation abnormalities (QST), were 
significantly more prevalent among HCM probands than 
among their G+/LVH+relatives. The G+/LVH- relatives were 
less likely to have a normal ECG than their unaffected 
relatives. P- values were adjusted for age, sex and within- 
family correlation. P- values<0.05 are shown for comparison 
between HCM probands and G+/LVH+relatives, as well as 
G+/LVH- relatives vs controls.
after the age of 60 years, indicating an approximate 
20- year delay in the penetrance of clinically detectable 
disease for female G+ relatives. Older male and female 
mutation carriers had an equal prevalence of LVH, indi-
cating that the Icelandic founder mutation is associated 
with a high lifetime penetrance of HCM. Whether these 
differences are related to long- term effects of endoge-
nous oestrogens or other factors is unclear.17 Additionally, 
identifying factors that render certain mutation- carriers 
resilient to developing HCM, even at advanced ages, is a 
high priority.
Relatives with lVH
The Icelandic G+/LVH+ relatives diagnosed through 
family screening had less advanced disease (few symptoms, 
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Figure 5 Clustered bar chart demonstrating the proportion 
(and 95% CI) of MYBPC3 c.927- 2A>G mutation carriers 
identified through family screening with clinical evidence of 
LVH, by age and gender.



























Diagnosed by family screening       100% 100% 72%
Male (%) 67% 67% 74% 55% 57% 59%
Age at diagnosis 41±14 44±14 36±16 50±19 47±16 44±19
LVWT, mean (mm) 25 20 23 18 16 19
LVOT gradient>30 mm Hg (%) 15% 28% 16% 0% 4% 14%
Left atrial diameter, mean (mm) 42 45 49 40 40 45
Diastolic dysfunction (%) 62% 56% N/A 29% 38% N/A
NYHA class≥2 (%) 48% 48% 58% 0% 8% 28%
Atrial fibrillation (%) 18% 21% 21% 8% 7% 14%
SCD/aborted SCD (%) 8% 14% 32% 0% 4% 7%
ICD (%) 18% 23% 58% 0% 13% 14%
*Clinical data from Dutch subjects with MYBPC3 founder mutations reported in.2
†Clinical data from Italian subjects with a MYBPC3 founder mutation reported in.1
G+, genotype- positive; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; LVH, left ventricular hypertrophy; 
LVOT, left ventricular outflow tract; LVWT, left ventricular wall thickness; MYBPC3, myosin- binding protein C; NYHA, New York Heart 
Association; SCD, suden cardiac death.
lower maximal LVWT, smaller LA, less obstructive physi-
ology and less prevalent diastolic dysfunction) despite 
older age at diagnosis compared with HCM probands. In 
addition, the prototypical HCM morphology of reverse 
curvature septal hypertrophy was less common in G+/
LVH+ relatives than in the probands (p=0.019). Assess-
ments of ECG abnormalities, systolic and early diastolic 
tissue Doppler velocities, and hsTnI and NT- proBNP 
confirmed milder clinical expression in G+/LVH+ rela-
tives than in HCM probands.
These findings are a vivid demonstration of the pheno-
typic variability possible with a single pathogenic muta-
tion. Factors that drive the marked heterogeneity in 
disease expression and clinical outcomes are poorly 
understood. By anchoring to a single pathogenic variant, 
further detailed studies of founder populations will 
provide valuable opportunities to better refine genotype–
phenotype correlations and to better understand features 
that contribute to phenotypic heterogeneity.
Comparisons with other studies of MYBPC3 founder 
mutations
Multiple founder mutations have been identified in 
MYBPC3,1 4–7 that all cause premature truncation and 
haploinsufficiency of myosin- binding protein in sarco-
meres. The effects of three Dutch founder mutations 
(46% MYBPC3 c.2373dupG; 32% MYBPC3 c.2827C>T; 
22% MYBPC3 c.2864_2865delCT) were characterised 
in 134 HCM probands and 54 G+/LVH+ relatives, iden-
tified by family screening,2 similar to our approach. An 
Italian study of the MYBPC3 p.F305Pfs*27 founder muta-
tion1 characterised 19 HCM probands and 29 G+/LVH+ 
relatives who were identified either by family screening 
(72%) or clinical presentation (28%). Across these 
founder mutation populations, HCM probands had a 
similar predominance of male sex, age of clinical diag-
nosis, maximum LVWT and prevalence of NYHA ≥2 func-
tional class. Among Dutch and Icelandic G+/LVH+ rela-
tives diagnosed by family screening, clinical features were 
also remarkably consistent and milder than those in HCM 
probands (table 3). Although previous studies underscore 
the heterogeneous nature of HCM even among individ-
uals with identical mutations18 and attribute these differ-
ences to genetic background and/or modifying environ-
mental factors and lifestyles, we observed remarkable 
phenotypic similarities among cohorts of HCM probands 
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and G+/LVH+ relatives with different MYPBC3 founder 
mutations. Given the distinct genetic backgrounds of the 
Dutch and Icelandic populations, differences in envi-
ronments and lifestyle, these data provide evidence for 
relatively consistent direct or proximal consequences of 
MYBPC3 haploinsufficiency. However, the concordance 
between G+/LVH+ relatives may also indicate the pres-
ence of other common genetic modifiers that attenuates 
disease expression (relative to probands) despite the pres-
ence of pathogenic genotypes. Given the shared molec-
ular mechanisms between different truncating MYBPC3 
founder mutations and the statistical power achieved by 
combining multiple families with these mutations, collab-
orative genomic analyses may uncover important delete-
rious or protective alleles.
Preclinical HCM and early phenotypes
Early morphological and electrophysiological pheno-
types reported among sarcomere mutation carriers with 
normal LVWT include subtle changes in LV cavity size 
and geometry, impaired LV relaxation19–22 and ECG 
abnormalities.11 As most of these studies analysed small 
and/or heterogeneous cohorts, interpretation of these 
findings has been difficult.20 23 Our analyses of preclin-
ical HCM subjects with a shared founder MYBPC3 muta-
tion advances these findings. In all, 59 G+ relatives had 
no diagnostic criteria for HCM, including 10 individuals 
over 50 years of age. LVWT and LA dimensions were 
normal, although the ratio of LVWT to LVEDD and the 
relative wall thickness was slightly higher in G+/LVH− 
relatives compared with unaffected relatives. Diastolic 
function parameters were normal in 97% of G+/LVH 
and 95% of unaffected relatives, and no significant differ-
ence was detected in any parameter of LV relaxation 
and estimation of LV filling pressures. However, while 
NT- proBNP levels did not discriminate preclinical (G+/
LVH−) subjects from controls in prior studies,12 13 20 23 24 
levels were higher in our G+/LVH− compared with unaf-
fected relatives, although still within the normal range. 
ECG abnormalities, predominantly Q waves and repolar-
isation changes, were more prevalent among G+/LVH− 
individuals than among unaffected relatives (27% vs 15%; 
p=0.028) and may reflect early manifestations of HCM,11 
although with low positive predictive value. Overall, the 
composite phenotypic manifestations of these 59 G+/
LVH− adults were subtle. We suggest that analyses of the 
impact of genetics and lifestyle, and determination of 
how early phenotypic changes relate to development of 
clinically overt HCM are worthy of further study.
limitations
This was a cross- sectional study, and participants were 
only screened for the MYBPC3 c.927- 2A>G mutation. 
Therefore, we cannot exclude the possibility of addi-
tional variants that may contribute to clinical variability. 
This study involved families with at least one member 
with overt HCM due to the MYBPC3 c.927- 2A>G founder 
mutation, while we estimate that~85% of the founder 
mutation carriers in Iceland or approximately 950 indi-
viduals remain clinically undetected with unknown clin-
ical status.3 Similar to most HCM studies, this study is 
biassed towards individuals with clinical HCM diagnosis 
and their first- degree relatives, and it might be difficult to 
extrapolate the results SE findings to the whole founder 
population of Iceland. A larger population- based study 
would add to the current knowledge of disease pene-
trance and disease expression and possibly identify either 
genetic or environmental modifiers that have significant 
impact on disease manifestation.
COnClusIOns
Through comprehensive family screening of a nation-
wide cohort of Icelandic individuals carrying the same 
MYBPC3 founder mutation, we demonstrated that 
HCM occurs at an earlier age in men, but the lifetime 
penetrance appears to be high and equivalent in both 
men and women. Relatives diagnosed with HCM in the 
context of family screening were older at initial evalu-
ation and had a milder clinical phenotype than HCM 
probands. Furthermore, phenotypic manifestations of 
the Icelandic MYBPC3 founder mutation were remark-
ably similar to other distinct founder populations with 
truncating MYBPC3 variants suggesting a common 
effect in the context of haploinsufficiency in the myosin- 
binding protein. Finally, we found a higher prevalence of 
abnormal ECGs and subtle differences in LV geometry 
in G+/LVH– subjects compared with unaffected relatives. 
Collaborative longitudinal clinical and genetic studies 
are needed to identify factors that modify disease expres-
sion, drive phenotypic progression and lead to adverse 
clinical outcomes.
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